TandemAI

TandemAI is a pioneering company in the field of drug discovery, offering Discovery as a Service with a focus on integrating artificial intelligence (AI) and physics-based methodologies. The company’s platform features TandemViz™ 1.0, a user-friendly, web-based interface that facilitates the seamless integration of computational analyses with experimental data. TandemAI’s approach includes the use of physics-based molecular simulation to analyze the interactions and bindings of drugs with proteins in motion, alongside AI-driven data ingestion, computation, and modeling to generate valuable insights. With a fully integrated wet lab and an in-house supercomputing infrastructure optimized for drug discovery workflows, TandemAI collaborates extensively with the global scientific community to enhance the success rates of pre-clinical drug candidates. The recent injection of $35 million in Series A financing is set to further expand TandemAI’s integrated computational and wet lab solutions, accelerating the pace of drug discovery and broadening access to these advanced tools.